How Computational Biology is Transforming Drug R&D
The latest episode of Exchanges at Goldman Sachs premieres a new monthly feature: An examination of a topic at the center of conversations in the venture-capital community. This week,\xa0Goldman Sachs Research\u2019s Heath Terry explores the growing world of computational biology\u2014using the power of big data to revolutionize drug discovery, disease prevention and cancer detection. Terry talked to VCs like Lux Capital\u2019s Zavain Dar, who invests in emerging science and technology firms. \u201cIt feels like we\u2019re at the precipice of what I think will be a multi-decade revolution in how biology and chemistry are fundamentally practiced,\u201d explains Dar. Terry also spoke with James Field, CEO of computational-biology startup LabGenius, which is using machine learning to more easily identify useful proteins for the human body. \u201cIf we can deploy technology in building out some discovery platforms in a way that the learnings compound over time,\u201d says Field, \u201cthen it will dramatically change the economics of discovering and developing drug molecules.\u201d